Download PROPOSED CASE LOG REVISIONS PER REVIEW

PROPOSED CASE LOG REVISIONS PER REVIEW COMMITTEE FOR
DERMATOLOGY PROSPECTIVE TO JULY 1, 2014
Area
Level 1: Perform
Category
Excision - Benign or
Malignant
Minimums
50
*Role(s)
Surgeon
Level 1: Perform
Repair (Closure)
Simple/Intermediate/Co
mplex
50
Surgeon
Level 2: Observe
Mohs Micrographic
Surgery
15
Surgeon + Observed
Level 2: Observe
Laser - Combined
(Ablative,
Non-ablative,
Vascular)
15
Surgeon + Observed
Level 2: Observe
Botulinum Toxin
Chemodeinnervation
10
Surgeon + Observed
Level 2: Observe
Soft Tissue
Augmentation/Skin
Fillers
5
Surgeon + Observed
Level 2: Observe
Flaps and Grafts
(Split or Full)
13
Surgeon + Observed
Level 2: Observe
Nail Procedures
3
Surgeon + Observed
*Surgeon + Observe - indicates that a resident may gain credit in this category minimum by either
performing or observing.
1
©2014 Accreditation Council for Graduate Medical Education (ACGME)
LIST OF MEDICAL TOPICS FOR CASE LOG PROSPECTIVE TO JULY
2014
Log Each Encounter
Immunobullous disease
Connective tissue disease
High Risk Systemic Medication Management
Log Individual Patients Only
Once
Phototherapy
Patch testing
Indicate "Adult" or "Pediatric"
Yes
Yes
Logged encounters should include only those patients with whom the resident plays an active role in diagnosis or
management. “High Risk Systemic Medication Management” is the term the Committee has chosen to define patients
who are on immunomodulating/immunosuppressive or molecular targeted medications. This does not include patients on
isotretinoin or prednisone, as it is anticipated that these patients are commonly seen by all residents, and therefore
logging these patients is unnecessary. Examples of high-risk systemic medications residents should log include:
cyclosporine, methotrexate, acitretin, dapsone, mycophenolate mofetil, TNF antagonists, IL-12/23 antagonists, IL-17
antagonists, rituximab, thalidomide, lenalidomide, cyclophosphamide, daclizumab, ipilimumab, vemurafenib, vismodegib,
and other new and emerging molecular-based therapies.
Phototherapy patients include all NBUVB, BBUVB, PUVA, and UVA1 patients, but do not include those undergoing nonultraviolet light and laser-based technologies. Patch testing patients include patients evaluated for contact dermatitis and
who undergo patch testing of any type, to include TRUE testing or more extensive patch testing. In order to log a patient,
residents must be involved in the selection of the allergens to test for, and must interpret the patch test reactions in terms
of reaction type and clinical relevance.
2
©2014 Accreditation Council for Graduate Medical Education (ACGME)